A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 14 Dec 2016 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.
- 28 Oct 2016 Status changed from not yet recruiting to recruiting.
- 12 Oct 2016 Status changed from planning to not yet recruiting.